Characteristics of adverse events and clinical risks of Lecanemab based on FAERS data
Zhaohui Li1, Jun Gu1, Zhiqiang Du1
1Affiliated Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, Jiangsu 214151, China.
Objective:
This study aims to analyze the distribution of adverse events (AEs) related to Lecanemab in real-world settings based on FAERS database data.
Methods:
Using the FAERS database, AE data related to Lecanemab was collected from Q3 2023 to Q2 2024. Signal mining was conducted using frequency and Bayesian methods to identify positive signals associated with Lecanemab.
Results:
A total of 8,284,874 AE reports were collected, with 894 related to Lecanemab. Signal mining identified 22 SOCs, involving 46 PTs. Nervous system disorders had the highest report count, with Amyloid-Related Imaging Abnormalities (ARIA) being the most prominent AE, with high report numbers and signal strength, manifesting as brain edema, microhemorrhages, and iron deposits in the brain. Additionally, infusion-related reactions were common, including headache, chills, and fever. The study also revealed some new potential AEs, such as anger, cognitive disorder, disorientation, and abnormal dreams. Although these psychiatric symptoms had a lower report count, their high signal strength suggests that Lecanemab may impact patients' mental states. Rare but severe AEs, such as encephalitis, pancreatic carcinoma, and subdural hematoma, had low report numbers but high signal strength, highlighting potential risks for these severe events, especially in high-risk patients with relevant medical histories.
Conclusion:
This study unveils certain potential risks associated with Lecanemab in real-world applications. Further clinical studies are needed to validate these findings and provide guidance for safe medication practices.
More Related Videos
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
